Journal of the American Society of Nephrology, Vol 4, 58-61, Copyright © 1993 by American Society of Nephrology

REGULAR ARTICLES

Interleukin-6 receptor blockage ameliorates murine lupus nephritis

BA Kiberd
Department of Medicine, Queen's University, Kingston, Ontario, Canada.

The therapeutic effects of a neutralizing monoclonal antibody (mAb) to the interleukin-6 receptor (IL-6R) were examined in the MRL-lpr/lpr murine lupus nephritis model. Animals (15 wk old) were treated with ip mAb IL-6R for 5 wk. GFR in these mice at the end of this treatment period were comparable to those of congenic strain disease-resistant MRL-(+)/+ controls treated with rat immunoglobulin G (IgG) (254 +/- 61 versus 285 +/- 26 microL/min; P = not significant). GFR was significantly (P < 0.05) lower in lpr/lpr mice receiving ip rat IgG (disease controls) at the same time (165 +/- 76 microL/min). The fractional mesangial volume (Mv) and surface density of open glomerular capillaries (Sv) in mAb II-6R-treated lpr/lpr and IgG-treated +/+ mice (Mv, 0.21 +/- 0.04 and 0.19 +/- 0.04 micron3/micron3; Sv, 0.18 +/- 0.01 and 0.20 +/- 0.01 micron/micron2, respectively) were similar. However, Mv (0.40 +/- 0.04) was significantly higher (P < 0.001) and Sv (0.13 +/- 0.04) was lower (P < 0.01) in IgG-treated lpr/lpr animals. Treatment with mAb IL-6R significantly reduced anti-dsDNA antibody levels after Week 2 of treatment, but these values rebounded at Week 4. The late development of neutralizing antibodies and the increased secretion of IL-6 at Week 4 were likely responsible. Despite these events, neutralizing mAb to the IL-6R proved to be effective therapeutically, as demonstrated by preserved glomerular function and structure.

This article has been cited by other articles:

				S. Yung, R. C.W. Tsang, Y. Sun, J. K.H. Leung, and T. M. Chan Effect of Human Anti-DNA Antibodies on Proximal Renal Tubular Epithelial Cell Cytokine Expression: Implications on Tubulointerstitial Inflammation in Lupus Nephritis J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3281 - 3294. [Abstract] [Full Text] [PDF]

				M Aringer and J S Smolen Cytokine expression in lupus kidneys Lupus, January 1, 2005; 14(1): 13 - 18. [Abstract] [PDF]

				H. Schotte, B. Schluter, S. Rust, G. Assmann, W. Domschke, and M. Gaubitz Interleukin-6 promoter polymorphism (-174 G/C) in Caucasian German patients with systemic lupus erythematosus Rheumatology, April 1, 2001; 40(4): 393 - 400. [Abstract] [Full Text] [PDF]

				G. S Dean, J. Tyrrell-Price, E. Crawley, and D. A Isenberg Cytokines and systemic lupus erythematosus Ann Rheum Dis, April 1, 2000; 59(4): 243 - 251. [Full Text]

				H Sato, Y Akai, M Iwano, N Kurumatani, H Kurioka, A Kubo, T Yamaguchi, T Fujimoto, and K Dohi Association of an insertion polymorphism of angiotensinconverting enzyme gene with the activity of systemic lupus erythematosus Lupus, October 1, 1998; 7(8): 530 - 534. [Abstract] [PDF]

				H. B. Richards, M. Satoh, M. Shaw, C. Libert, V. Poli, and W. H. Reeves Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus J. Exp. Med., September 7, 1998; 188(5): 985 - 990. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673